Vaxart, Inc. financial data

Symbol
VXRT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
170 Harbor Way, Suite 300, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aviragen Therapeutics, Inc. (to 2/15/2018), Biota Pharmaceuticals, Inc. (to 4/13/2016), NABI BIOPHARMACEUTICALS (to 11/8/2012), NABI BIOPHARMACEUTICALS (to 6/29/2010), NABI /DE/ (to 2/14/2002), NORTH AMERICAN BIOLOGICALS INC (to 2/14/1996)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 184 % -64.4%
Debt-to-equity 76 % +74.9%
Return On Equity -110 % -10.7%
Return On Assets -62.8 % +9.72%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 227M shares +49.6%
Common Stock, Shares, Outstanding 227M shares +49.6%
Entity Public Float 110M USD -72%
Common Stock, Value, Issued 23K USD +53.3%
Weighted Average Number of Shares Outstanding, Basic 227M shares +49.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.93M USD +135%
Research and Development Expense 66.3M USD -10.3%
General and Administrative Expense 22.2M USD -5.91%
Operating Income (Loss) -71.7M USD +26.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -72.1M USD +18.9%
Income Tax Expense (Benefit) 258K USD +150%
Net Income (Loss) Attributable to Parent -72.3M USD +18.7%
Earnings Per Share, Basic -0.4 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22M USD -33.5%
Cash, Cash Equivalents, and Short-term Investments 58.7M USD +10.8%
Accounts Receivable, after Allowance for Credit Loss, Current 591K USD +39.4%
Other Assets, Current 439K USD
Assets, Current 66.5M USD +16.4%
Property, Plant and Equipment, Net 9.48M USD -26.7%
Operating Lease, Right-of-Use Asset 21.5M USD -16.4%
Intangible Assets, Net (Excluding Goodwill) 3.74M USD -16.4%
Goodwill 4.51M USD 0%
Other Assets, Noncurrent 842K USD -4.64%
Assets 167M USD +57.8%
Accounts Payable, Current 2.52M USD +88.5%
Employee-related Liabilities, Current 4.51M USD -1.36%
Accrued Liabilities, Current 6.76M USD +12.9%
Liabilities, Current 80.4M USD +613%
Operating Lease, Liability, Noncurrent 15.3M USD -14.6%
Other Liabilities, Noncurrent 421K USD +51.4%
Liabilities 98.2M USD +188%
Accumulated Other Comprehensive Income (Loss), Net of Tax 27K USD
Retained Earnings (Accumulated Deficit) -465M USD -18.4%
Stockholders' Equity Attributable to Parent 68.4M USD -4.31%
Liabilities and Equity 167M USD +57.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2M USD +13.4%
Net Cash Provided by (Used in) Financing Activities 18.2M USD +1181%
Net Cash Provided by (Used in) Investing Activities -5.02M USD -120%
Common Stock, Shares Authorized 350M shares +40%
Common Stock, Shares, Issued 228M shares +50%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.02M USD -431%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22M USD -33.7%
Deferred Tax Assets, Valuation Allowance 82.5M USD +24.4%
Deferred Tax Assets, Gross 90.2M USD +21.1%
Operating Lease, Liability 18.2M USD -11%
Depreciation 3.8M USD +9.1%
Payments to Acquire Property, Plant, and Equipment 131K USD -89.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -72.3M USD +18.3%
Lessee, Operating Lease, Liability, to be Paid 22.6M USD -15.4%
Property, Plant and Equipment, Gross 19.1M USD +1.04%
Operating Lease, Liability, Current 2.88M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.03M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.51M USD +5.52%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.39M USD -29.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.21M USD +4.66%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.57M USD +32.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.39M USD +3.54%
Operating Lease, Payments 2M USD +81.8%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 600K USD -35.1%
Deferred Tax Assets, Net of Valuation Allowance 7.74M USD -5.31%
Share-based Payment Arrangement, Expense 12.9M USD -6.87%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%